|Bid||157.60 x 1000|
|Ask||200.00 x 900|
|Day's range||177.40 - 181.55|
|52-week range||85.65 - 236.17|
|PE ratio (TTM)||N/A|
|Earnings date||31 Jul 2018 - 6 Aug 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||217.94|
Twitter CEO Jack Dorsey announced some major executive restructuring at the social media network on Thursday, as VP of product and engineering Ed Ho announced he would step down into a part-time position.
NEW YORK, June 28, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of EMCOR ...
bluebird bio, Inc. (BLUE) announced that new data from the completed Phase 1/2 Northstar (HGB-204) study in adolescents and adults with transfusion-dependent β-thalassemia (TDT) and any genotype, and its ongoing, Phase 3 Northstar-2 (HGB-207) multicenter clinical study of LentiGlobin™ investigational gene therapy in patients with TDT and non-β0/β0 genotypes, will be presented in an oral session on June 16 at the 23rd Annual Congress of the European Hematology Association by Franco Locatelli, M.D., Ph.D., of the IRCCS Ospedale Pediatrico Bambino Gesù of Rome, Italy. “The maturing data from HGB-204 and HGB-207 suggest that one-time treatment with LentiGlobin may address the underlying genetic cause of TDT.
bluebird bio, Inc. today announced new interim data from the ongoing HGB-206 Phase 1 multicenter clinical study of LentiGlobin investigational gene therapy in patients with severe sickle cell disease will be presented in an oral presentation on Saturday, June 16 at the 23rd Congress of the European Hematology Association by Julie Kanter, M.D., Medical University of South Carolina, Charleston, South ...
Investors may listen to the call by dialing (844) 825-4408 from locations in the United States or +1 (315) 625-3227 from outside the United States. To access the live webcasts of bluebird bio’s presentations and conference calls, please visit the “Events & Presentations” page within the Investors and Media section of the bluebird bio website at http://investor.bluebirdbio.com. Replays of the webcasts will be available on the bluebird bio website for 90 days following the events.
Bluebird Bio Inc. shares lifted 9% in Monday morning trade after the company and its partner, Celgene Corp. , released phase 1 clinical trial results for the CAR-T cell therapy bb2121 showing that median patients survived for 11.8 months without their cancer progressing. Celgene shares declined 0.7%. The trial focused on patients with late-stage relapsed/refractory multiple myeloma, and patients had tried several other treatments before bb2121, with a median of seven prior myeloma treatment regimens.
The updates from ASCO can be practice-changing for doctors, life-changing for patients, and — for investors — market-moving.
In this article I am going to calculate the intrinsic value of bluebird bio Inc (NASDAQ:BLUE) using the discounted cash flows (DCF) model. If you want to learn more aboutRead More...
Celgene Corporation and bluebird bio, Inc. today announced updated results from the ongoing CRB-401 phase I clinical study of bb2121, an investigational anti-B-cell maturation antigen CAR T cell therapy, in 43 patients with late-stage relapsed/refractory multiple myeloma.
Wall Street analysts expect the company to see a 40.9% rise in revenue to $459.8 million in Q2 2018. Incyte’s stock price has fallen nearly 51.7% over the last 12 months and nearly 29.6% in 2018 year-to-date. Wall Street analysts’ recommendations show a 12-month target price of $81.0 per share compared to its price of $66.67 per share on May 24.
David reviews why the Fool continues to recommend the volatile bluebird bio and why he invests in companies like it.
It's an especially motley show today: a little of this, a little of that, thoughts from an old show, a new essay, some borrowed wisdom, and a BLUE stock pick. And, hey, what's that in your shoe?
In the first quarter, Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million. Analysts expect Ionis’s top line to rise ~30.2% to ~$135.7 million in the second quarter. The chart below shows analysts’ recommendations for Ionis stock over the last year.
bluebird bio, Inc. (BLUE) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Lenti-D™ for the treatment of patients with cerebral adrenoleukodystrophy (CALD), a rare, serious and life-threatening hereditary neurological disorder. Breakthrough Therapy designation is designed to expedite the development and review of a drug intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. “The founding of bluebird was inspired by the potential to develop a one-time gene therapy for boys suffering from this potentially fatal form of adrenoleukodystrophy,” said David Davidson, M.D., chief medical officer, bluebird bio.
BlueBird Bio (BLUE) is a biotechnology company focused on developing gene therapy, cancer immunotherapy, and gene editing for the treatment of serious diseases. On May 17, Bluebird Bio (BLUE) stock jumped over 6.1% to the closing price of $189.30 per share, following positive news.
bluebird bio, Inc. announced that data from ongoing LentiGlobin clinical studies in transfusion-dependent β-thalassemia and severe sickle cell disease will be highlighted in oral presentations at the 23rd Congress of the European Hematology Association .
bluebird bio, Inc. announced that updated interim data from CRB-401, its Phase 1 study of bb2121, an anti-BCMA CAR T cell therapy being developed by the company and Celgene, will be presented at the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois.
NEW YORK, May 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Aerohive ...
Both clinical-stage biotechs have cutting-edge cancer therapies in their pipelines. But which stock wins in a head-to-head matchup?